DOCSLIB.ORG

Novel Missense Mutations in the Human Lysosomal Sialidase Gene in Sialidosis Patients and Prediction of Structural Alterations of Mutant Enzymes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Missense Mutations in the Human Lysosomal Sialidase Gene in Sialidosis Patients and Prediction of Structural Alterations of Mutant Enzymes B.J Hum Jochimsen Genet et(2002) al.: Stetteria 47:29–37 hydrogenophila © Jpn Soc Hum Genet and Springer-Verlag4600/29 2002 ORIGINAL ARTICLE Kohji Itoh · Yasunori Naganawa · Fumiko Matsuzawa Seiichi Aikawa · Hirofumi Doi · Naokazu Sasagasako Takeshi Yamada · Jun-ichi Kira · Takuro Kobayashi Alexey V. Pshezhetsky · Hitoshi Sakuraba Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes Received: Stptember 21, 2001 / Accepted: November 2, 2001 Abstract Three novel missense mutations in the human changes including the active site residues responsible for lysosomal sialidase gene causing amino acid substitutions binding the sialic acid carboxylate group. The W240R sub- (P80L, W240R, and P316S) in the coding region were stitution was deduced to influence the molecular surface identified in two Japanese sialidosis patients. One patient structure of a limited region of the constructed models, with a severe, congenital form of type 2 sialidosis was a which was also influenced by previously identified V217M compound heterozygote for 239C-to-T (P80L) and 718T-to- and G243R transversions. C (W240R). The other patient with a mild juvenile-onset phenotype (type 1) was a homozygote for the base substitu- Key words Lysosomal sialidase · Sialidosis · Molecular tion of 946C-to-T (P316S). None of these mutant cDNA modeling · Protective protein/cathepsin A · Galacto- products showed enzymatic activity toward an artificial sialidosis substrate when coexpressed in galactosialidosis fibroblastic cells together with protective protein/cathepsin A (PPCA). All mutants showed a reticular immunofluorescence distri- bution when coexpressed with the PPCA gene in COS-1 Introduction cells, suggesting that the gene products were retained in the endoplasmic reticulum/Golgi area or rapidly degraded Lysosomal sialidase (neuraminidase, EC 3.2.1.18) catalyzes in the lysosomes. Homology modeling of the structural the hydrolysis of the terminal sialic acid residues of changes introduced by the mutations predicted that the sialylated glycoconjugates. In mammals, the enzyme associ- P80L and P316S transversions cause large conformational ates with acid -galactosidase (EC 3.2.1.23) and protec- tive protein/cathepsin A (PPCA, EC 3.4.16.1) to form a K. Itoh1 (*) · Y. Naganawa · H. Sakuraba multienzyme complex in lysosomes (d’Azzo et al. 1982; Department of Clinical Genetics, The Tokyo Metropolitan Institute Verheijen et al. 1982, 1985; Hiraiwa et al. 1988; van der of Medical Science, Tokyo Metropolitan Organization for Medical Horst et al. 1989). In paticular, association with PPCA Research, Tokyo, Japan is essential for expression of the sialidase activity (d’Azzo F. Matsuzawa · S. Aikawa · H. Doi et al. 1982; van der Spoel et al. 1998). Sialidosis is an auto- Celestar Lexico Sciences, Chiba, Japan somal recessive metabolic inborn error caused by a genetic N. Sasagasako defect of lysosomal sialidase, which is accompanied by accu- Department of Neurology, Hamanomachi Hospital, Federation of mulation in tissues and urinary excretion of sialyloligo- Public Services and Affiliated Personal Aid Association, Fukuoka, Japan saccharides (reviewed by Lowden and O’Brien 1979; Thomas 2000). The clinical phenotypes of sialidosis are T. Yamada · J. Kira · T. Kobayashi† Department of Neurology, Neurological Institute, Graduate School classified in two major groups according to the age of onset of Medical Sciences, Kyushu University, Fukuoka, Japan (†deceased) and severity: late-onset type 1 sialidosis is a relatively mild A.V. Pshezhetsky form characterized by macular cherry-red spots and myo- Service de Génétique Médicale, Départment de Pédiatrie, Hôpital clonus, and early infantile-onset type 2 sialidosis is a severe Sainte-Justine, Université de Montréal, Montréal, Canada condition distinguished by the appearance of dysmorphic manifestations in addition to neurological symptoms and Present address: cherry-red spots. Sialidosis type 2 is further divided into 1 Division of Medicinal Biotechnology, Institute for Medicinal three clinical subtypes: congenital, infantile, and juvenile. Resources, Faculty of Pharmaceutical Sciences, University of The congenital form is the most severe subtype, and is Tokushima, 1-78 Sho-machi, Tokushima 770-8505, Japan Tel. ϩ81-88-633-7290; Fax: ϩ81-88-633-7290 associated with hydrops fetalis, neonatal ascites, edema, e-mail: [email protected] inguinal hernia, hepatosplenomegaly, and death at an early 30 N. Matsuda et al.: EGF receptor and osteoblastic differentiation age. Another human sialidase deficiency, galactosialidosis, the nonconsanguineous parents’ request, as previously de- is caused by a primary defect of PPCA with combined de- scribed (Sasagasako et al. 1993). The proband of the family creases in lysosomal sialidase, -galactosidase, and cathep- was the second female child of the parents, who was found sin A activities, and has clinical manifestations similar to to have hydrops fetalis in the 33rd gestational week. At those of sialidosis (reviewed by d’Azzo et al. 2000). birth, severe subcutaneous edema, pleural effusion, ascites, In recent years, the human lysosomal sialidase gene has and hepatosplenomegaly were observed. She was diag- been cloned (Bonten et al. 1996; Pshezhetsky et al. 1997; nosed as having a congenital form of type 2 sialidosis, and Milner et al. 1997) on the basis of the genomic and struc- she subsequently developed respiratory failure and died 87 tural information on the sialidases obtained from a variety days after birth. The male fetus was artificially aborted of species, including viruses and bacteria (Roggentin et al. in the 21st gestational week. A pathological study revealed 1989; Rothe et al. 1991; Crennell et al. 1993, 1994; Gaskell slight generalized subcutaneous edema, mild pleural effu- et al. 1995). The human sialidase cDNA contains a 1.2-kb sion, ascites, and mild hepatosplenomegaly. Light micro- open reading frame and a polyadenylation site within the 3Ј scopic analysis disclosed a large number of vacuoles in the untranslated region. The deduced amino acid sequence con- cytoplasm of the liver, spleen, skin, bone marrow, lymph tains four Asp boxes (S/T-X-D-S-G-X-X-W/F), which are nodes, adrenal cortex, anterior horn cells of the spinal cord, repeated at topologically equivalent positions, and a (F)RIP and neuronal cells in the cerebrum. sequence motif, which is part of the active site. In addition, the sequence revealed the presence of three potential Patient 2. The other patient is the 24-year-old male off- N-glycosylation sites and a carboxy-terminal Y-X-X- spring of consanguineous parents. At the age of 14 years, hydrophobic residue motif similar to that found in other he developed gait disturbance and dysgraphia. Generalized lysosomal integral membrane proteins (Guarnieri et al. convulsive seizure attacks, visual disturbance, dysarthria, 1993; Sosa et al. 1993). A number of mutations have been and action myoclonus were also observed. Physical exami- identified in sialidosis patients (Bonten et al. 1996; Bonten nation at 18 years of age revealed bilateral cherry-red spots and d’Azzo 2000; Pshezhetsky et al. 1997; Lukong et al. and cerebellar dysfunction. He was diagnosed as having 2000; Naganawa et al. 2000). type 1 sialidosis. The progression of the symptoms was Conservation of the basic structural fold of sialidases, rapid. Difficulty in swallowing appeared by 18 years of age, which consists of six four-stranded antiparallel -sheets ar- and he suffered from recurrent bronchopneumonia. His ranged as the blades of a propeller around an axis of sym- elder brother died of sialidosis at 18 years of age, but metry passing through the active site, among various species detailed clinical data are not available. has also been shown (Crennell et al. 1993, 1994; Gaskell et al. 1995), which makes it possible to model the tertiary Cell culture structure of human lysosomal sialidase (Lukong et al. 2000; Naganawa et al. 2000). In the present study, we identified Human skin fibroblasts derived from the two patients with three new missense mutations resulting in amino acid sub- sialidosis were maintained in Ham’s F-10 medium supple- stitutions, and characterized the mutant products biochemi- mented with 10% fetal calf serum (FCS) and antibiotics. cally. Using homology modeling, we deduced the structural For transient expression of the wild-type and mutant changes in the structure of the sialidase molecule caused by sialidase cDNAs, a fibroblastic cell line derived from a the substitutions. galactosialidosis patient (ASVGS-1) (Shimmoto et al. 1993) or COS-1 cells (Gluzman 1988) was cultured in the same medium. Subjects and methods Gene analysis Subjects Total RNA and genomic DNA were isolated from the cul- Sialidosis patients were diagnosed biochemically by assay- tured fibroblasts as described previously (Davis et al. 1986). ing lysosomal enzymes (Suzuki et al. 1981; Suzuki 1987) in Lysosomal sialidase cDNA, including the entire coding cultured skin fibroblasts or amniocytes. All fibroblastic cell region, was obtained by reverse transcription (RT)- strains showed the isolated sialidase deficiency. Other polymerase chain reaction (PCR), and the nucleotide se- enzyme activities, including those of -galactosidase and quence was determined according to a previous report cathepsin A, were normal. (Naganawa et al. 2000). As described in the Results section, The research was carried out in accordance with the 239C-to-T (P80L), 718T-to-C (W240R),
Load more

Recommended publications
  • Human Cathepsin A/ Lysosomal Carboxypeptidase a Antibody
    Human Cathepsin A/ Lysosomal Carboxypeptidase A Antibody Monoclonal Mouse IgG2A Clone # 179803 Catalog Number: MAB1049 DESCRIPTION Species Reactivity Human Specificity Detects human Cathepsin A/Lysosomal Carboxypeptidase A in direct ELISAs and Western blots. In Western blots, detects the single chain (55 kDa) and heavy chain (32 kDa) forms of recombinant human (rh) Cathepsin A. In Western blots, less than 5% cross­reactivity with rhCathepsin B, C, D, E, L, O, S, X and Z is observed and no cross­reactivity with the light chain (20 kDa) of rhCathepsin A is observed. Source Monoclonal Mouse IgG2A Clone # 179803 Purification Protein A or G purified from hybridoma culture supernatant Immunogen Mouse myeloma cell line NS0­derived recombinant human Cathepsin A/Lysosomal Carboxypeptidase A Ala29­Tyr480 (predicted) Accession # P10619 Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (­SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS. APPLICATIONS Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website. Recommended Sample Concentration Western Blot 1 µg/mL Recombinant Human Cathepsin A/Lysosomal Carboxypeptidase A (Catalog # 1049­SE) Immunoprecipitation 25 µg/mL Conditioned cell culture medium spiked with Recombinant Human Cathepsin A/Lysosomal Carboxypeptidase A (Catalog # 1049­SE), see our available Western blot detection antibodies PREPARATION AND STORAGE Reconstitution Reconstitute at 0.5 mg/mL in sterile PBS. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
    [Show full text]
  • Neuroradiologic Findings in Fucosidosis, a Rare Lysosomal Storage Disease
    Neuroradiologic Findings in Fucosidosis, a Rare Lysosomal Storage Disease James M. Provenzale, Daniel P. Barboriak, and Katherine Sims Summary: Fucosidosis is a rare lysosomal storage disorder with vacuolated secondary lysosomes containing some fine the clinical features of mental retardation, cardiomegaly, dysos- fibrillar material and lamellated membrane structures. tosis multiplex, progressive neurologic deterioration, and early A magnetic resonance (MR) examination at the age of death. The neuroradiologic findings in two patients are reported, 10 years showed confluent regions of hyperintense signal and include abnormalities within the globus pallidus (both pa- on T2-weighted images in the periventricular regions, tients) and periventricular white matter (one patient). most prominent surrounding the atria of the lateral ventri- cles. Hyperintense signal was noted in the globus pallidus Index terms: Brain, metabolism; Degenerative disease, Pediatric on T1-weighted images, with corresponding hypointense neuroradiology signal on T2-weighted images (Fig 1). Fucosidosis is a rare metabolic disorder caused by decreased amounts of the enzyme Case 2 a-L-fucosidase, which results in the accumula- A 2-year-old boy was examined for speech delay and tion of fucose-rich storage products within psychomotor retardation. He was born at term after a many organs, including the brain. Patients with normal pregnancy, and appropriate development oc- this disorder usually have delayed intellectual curred during the first year of life. However, by age 2 years, and motor development, and often die within the patient had not developed speech, exhibited autistic the first decade of life. Computed tomographic behavior, and performed motor tasks poorly. Physical ex- (CT) findings have been reported in a few cases amination findings included coarsened facial features, nar- (1, 2).
    [Show full text]
  • Assessing Mimicry of the Transition State
    View Article Online / Journal Homepage / Table of Contents for this issue PERSPECTIVE www.rsc.org/obc | Organic & Biomolecular Chemistry Glycosidase inhibition: assessing mimicry of the transition state Tracey M. Gloster*a,b and Gideon J. Davies*a Received 5th August 2009, Accepted 30th September 2009 First published as an Advance Article on the web 5th November 2009 DOI: 10.1039/b915870g Glycoside hydrolases, the enzymes responsible for hydrolysis of the glycosidic bond in di-, oligo- and polysaccharides, and glycoconjugates, are ubiquitous in Nature and fundamental to existence. The extreme stability of the glycosidic bond has meant these enzymes have evolved into highly proficient catalysts, with an estimated 1017 fold rate enhancement over the uncatalysed reaction. Such rate enhancements mean that enzymes bind the substrate at the transition state with extraordinary affinity; the dissociation constant for the transition state is predicted to be 10-22 M. Inhibition of glycoside hydrolases has widespread application in the treatment of viral infections, such as influenza and HIV, lysosomal storage disorders, cancer and diabetes. If inhibitors are designed to mimic the transition state, it should be possible to harness some of the transition state affinity, resulting in highly potent and specific drugs. Here we examine a number of glycosidase inhibitors which have been developed over the past half century, either by Nature or synthetically by man. A number of criteria have been proposed to ascertain which of these inhibitors are true transition state mimics, but these features have only be critically investigated in a very few cases. Introduction molecules, lipids or proteins), constitute between 1 and 3% of the genome of most organisms.1 The task facing these enzymes Glycosidases, the enzymes responsible for the breakdown of di-, with respect to maintaining efficient and highly specific catalysis oligo- and polysaccharides, and glyconjugates, are ubiquitous is no mean feat; it has been calculated that there are 1.05 ¥ 1012 through all kingdoms of life.
    [Show full text]
  • Oxidative Stress, a New Hallmark in the Pathophysiology of Lafora Progressive Myoclonus Epilepsy Carlos Romá-Mateo *, Carmen Ag
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Digital.CSIC 1 Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy Carlos Romá-Mateo1,2*, Carmen Aguado3,4*, José Luis García-Giménez1,2,3*, Erwin 3,4 3,5 1,2,3# Knecht , Pascual Sanz , Federico V. Pallardó 1 FIHCUV-INCLIVA. Valencia. Spain 2 Dept. Physiology. School of Medicine and Dentistry. University of Valencia. Valencia. Spain 3 CIBERER. Centro de Investigación Biomédica en Red de Enfermedades Raras. Valencia. Spain. 4 Centro de Investigación Príncipe Felipe. Valencia. Spain. 5 IBV-CSIC. Instituto de Biomedicina de Valencia. Consejo Superior de Investigaciones Científicas. Valencia. Spain. * These authors contributed equally to this work # Corresponding author: Dr. Federico V. Pallardó Dept. Physiology, School of Medicine and Dentistry, University of Valencia. E46010-Valencia, Spain. Fax. +34963864642 [email protected] 2 ABSTRACT Lafora Disease (LD, OMIM 254780, ORPHA501) is a devastating neurodegenerative disorder characterized by the presence of glycogen-like intracellular inclusions called Lafora bodies and caused, in most cases, by mutations in either EPM2A or EPM2B genes, encoding respectively laforin, a phosphatase with dual specificity that is involved in the dephosphorylation of glycogen, and malin, an E3-ubiquitin ligase involved in the polyubiquitination of proteins related with glycogen metabolism. Thus, it has been reported that laforin and malin form a functional complex that acts as a key regulator of glycogen metabolism and that also plays a crucial role in protein homeostasis (proteostasis). In relationship with this last function, it has been shown that cells are more sensitive to ER-stress and show defects in proteasome and autophagy activities in the absence of a functional laforin-malin complex.
    [Show full text]
  • The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue
    The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue JOHN F. TALLMAN, WILLIAM G. JOHNSON, and ROSCOE 0. BRADY From the Developmental and Metabolic Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland 20014, and the Department of Biochemistry, Georgetown University School of Medicine, Washington, D. C. 20007 A B S T R A C T The catabolism of Tay-Sachs ganglioside, date fronm the 19th century and over 599 cases have been N-acetylgalactosaminyl- (N-acetylneuraminosyl) -galac- reported (1). Onset of the disease is in the first 6 months tosylglucosylceramide, has been studied in lysosomal of life and is characterized by apathy, hyperacusis, motor preparations from normal human brain and brain ob- weakness, and appearance of a macular cherry-red spot tained at biopsy from Tay-Sachs patients. Utilizing Tay- in the retina. Seizures and progressive mental deteriora- Sachs ganglioside labeled with '4C in the N-acetylgalac- tion follow with blindness, deafness, and spasticity, lead- tosaminyl portion or 3H in the N-acetylneuraminosyl ing to a state of decerebrate rigidity. These infants usu- portion, the catabolism of Tay-Sachs ganglioside may be ally die by 3 yr of age (2). initiated by either the removal of the molecule of A change in the chemical composition of the brain of N-acetylgalactosamine or N-acetylneuraminic acid. The such patients was first detected by Klenk who showed activity of the N-acetylgalactosamine-cleaving enzyme that there was an increase in the ganglioside content (hexosaminidase) is drastically diminished in such compared with normal human brain tissue (3).
    [Show full text]
  • Program Download
    5TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE ROME, ITALY NOVEMBER 1-4 2017 EMBRACING INNOVATION ADVANCING THE CURE ISMRD would like to say a very special thank you to the following organizations and companies who have very generously given donations to support the 5th International Conference on Glycoproteinoses. THE WAGNER FOUNDATION ISMRD is very grateful for all the help and support that Symposia has given us in the organization of our Conference on-the-ground support in Rome. Dedicated to helping patients in the rare disease community with unmet medical needs Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company committed to creating new therapeutics to combat serious, debilitating diseases. www.ultragenyx.com © 2017 Ultragenyx Pharmaceutical Inc. www.ultragenyx.com 8/16 MRCP-UGNX-00008 5TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE 2017 Welcome to Rome! On behalf of ISMRD, I would like to welcome Of course, our conference would not take you all to the Fifth Glycoproteinoses place without significant charitable donations. International Conference on 'Embracing I would like to thank the following companies Innovation and Advancing the Cure'. and foundations, Ultragenyx, EveryLife Foundation, Sanofi/Genzyme, Amicus and The ISMRD is thrilled to bring our International Wagner Foundation. I would also like to extend Conference to Europe allowing us to connect our very grateful thanks to Symposia who are with families, researchers, clinicians, support event planners, who have worked alongside us groups and others who work in the field of rare here in Rome and have helped you check in at diseases. But, more importantly to help make registration. They will be on site throughout the the invaluable connections for families who meeting offering support and answering any perhaps have never met another family with questions you may have.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Summary of Neuraminidase Amino Acid Substitutions Associated with Reduced Inhibition by Neuraminidase Inhibitors
    Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors. Susceptibility assessed by NA inhibition assays Source of Type/subtype Amino acid N2 b (IC50 fold change vs wild type [NAI susceptible virus]) viruses/ References Comments substitutiona numberinga Oseltamivir Zanamivir Peramivir Laninamivir selection withc A(H1N1)pdm09 I117R 117 NI (1) RI (10) ? ?d Sur (1) E119A 119 NI/RI (8-17) RI (58-90) NI/RI (7-12) RI (82) RG (2, 3) E119D 119 RI (25-23) HRI (583-827) HRI (104-286) HRI (702) Clin/Zan; RG (3, 4) E119G 119 NI (1-7) HRI (113-1306) RI/HRI (51-167) HRI (327) RG; Clin/Zan (3, 5, 6) E119V 119 RI (60) HRI (571) RI (25) ? RG (5) Q136K/Q 136 NI (1) RI (20) ? ? Sur (1) Q136K 136 NI (1) HRI (86-749) HRI (143) RI (42-45) Sur; RG; in vitro (2, 7, 8) Q136R was host Q136R 136 NI (1) HRI (200) HRI (234) RI (33) Sur (9) cell selected D151D/E 151 NI (3) RI (19) RI (14) NI (5) Sur (9) D151N/D 151 RI (22) RI (21) NI (3) NI (3) Sur (1) R152K 152 RI(18) NI(4) NI(4) ? RG (3, 6) D199E 198 RI (16) NI (7) ? ? Sur (10) D199G 198 RI (17) NI (6) NI (2) NI (2) Sur; in vitro; RG (2, 5) I223K 222 RI (12–39) NI (5–6) NI (1–4) NI (4) Sur; RG (10-12) Clin/No; I223R 222 RI (13–45) NI/RI (8–12) NI (5) NI (2) (10, 12-15) Clin/Ose/Zan; RG I223V 222 NI (6) NI (2) NI (2) NI (1) RG (2, 5) I223T 222 NI/RI(9-15) NI(3) NI(2) NI(2) Clin/Sur (2) S247N 246 NI (4–8) NI (2–5) NI (1) ? Sur (16) S247G 246 RI (15) NI (1) NI (1) NI (1) Clin/Sur (10) S247R 246 RI (36-37) RI (51-54) RI/HRI (94-115) RI/HRI (90-122) Clin/No (1)
    [Show full text]
  • File Download
    Radiological and clinical characterization of the lysosomal storage disorders: non-lipid disorders Minzhi Xing, Emory University E I Parker, Emory University A Moreno-De-Luca, Geisinger Health System Elie Harmouche, Emory University Michael Terk, Emory University Journal Title: British Journal of Radiology Volume: Volume 87, Number 1033 Publisher: British Institute of Radiology | 2014-01-01, Pages 20130467-20130467 Type of Work: Article | Final Publisher PDF Publisher DOI: 10.1259/bjr.20130467 Permanent URL: https://pid.emory.edu/ark:/25593/pr2p5 Final published version: http://dx.doi.org/10.1259/bjr.20130467 Copyright information: © 2014 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits distribution of derivative works, making multiple copies, distribution, public display, and publicly performance, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author, copyright and license notices be kept intact. Accessed September 24, 2021 3:09 PM EDT BJR © 2014 The Authors. Published by the British Institute of Radiology Received: Revised: Accepted: doi: 10.1259/bjr.20130467 28 July 2013 29 October 2013 8 November 2013 Cite this article as: Xing M, Parker EI, Moreno-De-Luca A, Harmouche E, Terk MR. Radiological and clinical characterization of the lysosomal storage disorders: non-lipid disorders. Br J Radiol 2014;87:20130467. REVIEW ARTICLE Radiological
    [Show full text]
  • Fast Urinary Screening of Oligosaccharidoses by MALDI-TOF/TOF Mass Spectrometry
    Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry. Laurent Bonesso, Monique Piraud, Céline Caruba, Emmanuel van Obberghen, Raymond Mengual, Charlotte Hinault To cite this version: Laurent Bonesso, Monique Piraud, Céline Caruba, Emmanuel van Obberghen, Raymond Mengual, et al.. Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry.. Orphanet Journal of Rare Diseases, BioMed Central, 2014, 9 (1), pp.19. 10.1186/1750-1172-9-19. inserm- 00945684 HAL Id: inserm-00945684 https://www.hal.inserm.fr/inserm-00945684 Submitted on 12 Feb 2014 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Bonesso et al. Orphanet Journal of Rare Diseases 2014, 9:19 http://www.ojrd.com/content/9/1/19 RESEARCH Open Access Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry Laurent Bonesso1, Monique Piraud5, Céline Caruba1, Emmanuel Van Obberghen1,2,3,4, Raymond Mengual1† and Charlotte Hinault1,2,3,4*† Abstract Background: Oligosaccharidoses, which belong to the lysosomal storage diseases, are inherited metabolic disorders due to the absence or the loss of function of one of the enzymes involved in the catabolic pathway of glycoproteins and indirectly of glycosphingolipids.
    [Show full text]
  • Lysosomal Diseases
    THE GLYCOPROTEINOSES: SECOND INTERNATIONAL WORKSHOP ON ADVANCES IN PATHOGENESIS AND THERAPY JULY 26-27, 2007 ANN ARBOR, MICHIGAN Scientific Conference Day 1 Morning Sessions, July 26 7:30-8:15 Continental Breakfast 8:15-8:30 Welcome and Introductions, Opening Remarks – Goals of the conference, progress since the last conference - Steven Walkley (with additional comments by officials from ISMRD, NINDS, ORD) 8:30-9:15 Plenary Address Cross-Correction: Looking Back, Looking Forward – Elizabeth Neufeld Session 1: Animal Models, Pathogenesis, Experimental Therapies (Chair, Mark Haskins) α-Mannosidosis 9:15-9:35 Enzyme replacement therapy for α-Mannosidosis - Judith Blanz 9:35-9:55 α-Mannosidosis in the Guinea Pig – Pathophysiological, behavioral, and treatment issues - John Hopwood 10:00-10:15 Break α-Mannosidosis (continued) 10:15-10:35 Strategies for translating gene therapy in the brain from rodents to clinical use - John Wolfe 10:35-10:55 Quantitative Imaging of gray matter disease associated with feline α- mannosidosis – Charles Vite β-Mannosidosis 10:55-11:15 β-Mannosidosis mice – A model for the human disease? – Karen Friderici Fucosidosis 11:15-11:30 Intrathecal enzyme infusion therapy in canine fucosidosis – Gauthami Kondagari 11:30-12:00 General Discussion 12:00-1:30 Lunch Afternoon Session, July 26 1:30-2:15 Special Lecture: The Glycoproteinoses: Limited Progress in Molecular Insight still Surpasses Present-day Treatment Efficacy – Jules Leroy Session 2: Animal Models, Pathogenesis, Experimental Therapies (Chair, John Wolfe)
    [Show full text]
  • 4Th Glycoproteinoses International Conference Advances in Pathogenesis and Therapy
    Program & Abstracts 4TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE ADVANCES IN PATHOGENESIS AND THERAPY ISMRD ST. LOUIS, MISSOURI, UNITED STATES Program & Abstracts I SM R D ADVANCES IN PATHOGENESIS AND THERAPY Program & Abstracts ISMRD would like to say A Very Special Thank You to the following organizations and companies who have very generously given donations and sponsorship to support the 4th International Conference on Glycoproteinoses THE PRENILLE EDWARD MALLINCKRODT FOUNDATION JR FOUNDATION MARK HASKINS I SM R D 4TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE 2015 ADVANCES IN PATHOGENESIS AND THERAPY Program & Abstracts ISMRD is very proud to display 10 featured Expression of Hope artworks to be Auctioned at the Gala Dinner. These beautiful prints are from Genzyme’s featured Artwork selection. Contents Welcome 1 SCIENTIFIC COMMITTEE: Stuart Kornfeld ISMRD Mission & Governance 3 (Chair, Scientifi c Planning Committee) Steve Walkley Sara Cathey ISMRD General Information 5 Richard Steet Sean Thomas Ackley, Philippines Miriam Storchli, Switzerland Alessandra d’Azzo ‘Hope’ by Sarah Noble, New Zealand Scientifi c Program 9 FAMILY CONFERENCE COMMITTEE: Family Program for Mucolipidosis 11 Jenny Noble (Conference Organiser) Jackie James (Conference Organiser Family Program For Alpha Mannosidosis /Sialidosis/ 13 - St. Louis) Fucosidosis/Aspartylglucosaminuria Mark Stark John Forman ‘All around the world’ by Zih Yun Li , Taiwan Childrens Program 16 Susan Kester Carolyn Paisley-Dew Tish Adkins Abstracts 17 Sara DeAngelis, Russia Gayle Rose, United States Speaker Profi les 60 Delegates 81 Helen Walker, Australia Nicklas Harkins, Canada Naomi Arai, Japan David Wentworth, Serbia I SM R D 4TH GLYCOPROTEINOSES INTERNATIONAL CONFERENCE 2015 ADVANCES IN PATHOGENESIS AND THERAPY Program & Abstracts On behalf of the Scientifi c Planning Committee, I want to extend a warm welcome to all the investigators and Welcome! families who have traveled to St.
    [Show full text]